Find investors
← Back to all investors
RF
ResearchedAngel Investors

Richard Falconer

Chief Financial Officer

Angel InvestorsSeed Round
Pitch Richard

Get their honest, personalized take on your startup.

Sign in to pitch Richard

At a glance

Full Name
Richard "Rick" Falconer
Title
Senior Managing Director
Firm
Coremix Capital, LLC
Firm Type
Family office / private equity investor
Investment Stage
Growth financing, recapitalizations, buyouts, acquisition financings, corporate divestitures, sponsored and unsponsored transactions
Check Size
$1 million to $15 million initial investments
Target Company Profile
U.S. middle-market companies that need subordinated debt and/or equity capital, operational guidance, and growth capital
Sector Focus
Consumer products, food, life science, manufacturing, real estate, healthcare services, education, machinery, medical products, software, consumer-focused technology, gaming, and mobile/software
Geographic Focus
United States
Location
Vancouver, Washington

Background

Richard "Rick" Falconer is a Senior Managing Director at Coremix Capital, LLC, a Vancouver, Washington-based family office and investment firm founded in 2013. Coremix describes itself as the investment and management arm of a family office, with specialties including acquisition and growth financings, accounts receivable financing, real estate acquisitions, equipment leasing/purchases, and brand building.

Before Coremix, Falconer was Chief Financial Officer of Avid Health, Inc., the Vancouver-based maker of Vitafusion and L'il Critters gummy vitamins. In Church & Dwight's 2012 stock purchase agreement for Avid Health, Richard Falconer signed on behalf of Avid Health as Chief Financial Officer. Church & Dwight completed the Avid Health acquisition on October 1, 2012 for approximately $650 million; its 2012 annual report recorded the purchase price at $652.3 million.

Falconer's earlier career included finance roles at Interlogix Corp., General Electric, and Arthur Andersen LLP. MarketScreener lists him as previously VP Finance at Interlogix, Audit Manager at Arthur Andersen, and a principal at General Electric. His education is listed as Oregon State University.

Investment Thesis & Focus

  • Coremix provides flexible capital across the debt-equity spectrum, combining financing with business insight and operational guidance.
  • The firm says: "Initial investments range from $1 to $15 million."
  • Coremix invests in companies "at all stages of their development," but its disclosed deal history is concentrated in growth capital and middle-market financing rather than seed angel investing.
  • Transaction types include recapitalizations, management-led buyouts, growth financing, corporate divestitures, acquisition financings, and sponsored or unsponsored transactions.
  • Coremix emphasizes founder/operator support: it says it understands entrepreneurs, has "a passion for growing companies," and focuses on translating vision into execution, managing risk, and maximizing profitability.
  • Falconer's MobileRQ quote suggests interest in category growth and customer engagement: he said MobileRQ could help customers "engage with consumers in significant ways whenever and wherever they are."

Notable Investments

  • MobileRQ - Portland contextual mobile marketing platform for travel, hospitality, loyalty, and retail brands; Coremix participated in a June 2014 round alongside Verizon Ventures, Rogue Ventures, and TiE Oregon.
  • Consensus Orthopedics - El Dorado Hills medical products company designing and distributing reconstructive hip and knee implants; Mergr lists Coremix as a seller when Shalby acquired the company on May 17, 2021 for $11 million.
  • BMM Testlabs / BMM International - Las Vegas gaming testing, certification, and regulatory compliance business; Mergr lists Coremix as an investor in an August 1, 2013 growth capital transaction.
  • Avid Health - Not a Coremix investment, but a central operating background for Falconer and the Coremix founding group; Church & Dwight acquired Avid Health in 2012 for approximately $650 million.

Unlock the full research

Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.

One-time. Stays unlocked for you.